LearnGlossaryMarketStocksSuperinvestorsSign in

YDES

YD Bio Limited Ordinary Shares

Healthcare · $492M market cap

Verdict

We can't put a fair value on YDES right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth—?
Sales growth30.6% a year✓
Free cash flow growth—?
Return on invested capital-25.4%✗

Follow YDES

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 4, 2026: 2 open-market purchases worth $80K. Why purchases matter

Purchases

Shen Ethan PhD

CEO · 2026-09-09

Bought

$12K

Shen Ethan PhD

CEO · 2026-09-04

Bought

$67K

About YD Bio Limited Ordinary Shares

Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works